Rhelion Life Sciences Corp. RHEL
CNSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -78.94% | -29.66% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -78.94% | -29.66% | |||
| Cost of Revenue | -96.12% | -53.30% | |||
| Gross Profit | -63.33% | 30.23% | |||
| SG&A Expenses | -1.96% | 1.37% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.99% | -18.84% | |||
| Operating Income | -30.89% | 7.38% | |||
| Income Before Tax | 56.68% | -142.28% | |||
| Income Tax Expenses | -- | -733.66% | |||
| Earnings from Continuing Operations | 53.51% | -130.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -96.72% | 2,005.60% | |||
| Net Income | 26.82% | -86.32% | |||
| EBIT | -30.89% | 7.38% | |||
| EBITDA | -32.93% | 7.44% | |||
| EPS Basic | 44.19% | -79.17% | |||
| Normalized Basic EPS | -- | 100.00% | |||
| EPS Diluted | 44.19% | -79.17% | |||
| Normalized Diluted EPS | -- | 100.00% | |||
| Average Basic Shares Outstanding | 29.86% | 1.69% | |||
| Average Diluted Shares Outstanding | 29.86% | 1.69% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||